Fig. 9From: Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention Pharmacokinetic profiles of voriconazole (VRC) and lipid-polymer hybrid nanoparticles (LPH NPs) at different time-points in (a) Lungs and (b) Plasma, following nebulization for 20 min to Balb/c mice through inhouse nose-only inhalation chamber. Data expressed in mean ± SD, n = 3 mice/group. The corresponding inset depicts percent change in different pharmacokinetic parametersBack to article page